Cerevel Puts Tavapadon Into Phase III for Parkinson’s
Recruiting 1,200 Patients
The company, launched in October 2018 with neuroscience programs spun out from Pfizer and supported by $350m from Bain, believes it has a treatment that could prove effective across the full spectrum of Parkinson’s disease.
You may also be interested in...
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.
Yumanity Therapeutics has raised a $45m Series A venture capital round, which will fund continued drug discovery related to neurodegenerative diseases caused by protein misfolding, but the company's first clinical trials probably will be financed through additional financing or potential partnership agreements.